Integrated Pathways of Disease in NASH and NAFLD (Keystone A4 2019) | InSphero

Integrated Pathways of Disease in NASH and NAFLD (Keystone A4 2019)


Jan 20 - 24, 2019

Advancing NASH and NAFLD disease modeling

jump to section

Meet InSphero Head of Liver Solutions Dr. Eva Thoma at the Keystone Symposium on Integrated Pathways of Disease in NASH and NAFLD. Eva will be available throughout the meeting to discuss the latest advances in 3D in vitro models for studying obesity-related liver diseases such as:

  • Steatosis
  • Fibrosis
  • NASH

Schedule a Meeting

The first in vitro human model for NASH drug discovery

Wednesday, January 23, 7:30 – 10 PM
Poster Session 3, Poster Number 3015

Dr. Thoma will present the latest data on using our 3D human liver microtissues to model NASH progression in vitro for drug discovery and safety testing. Our 3D InSight™ Human Liver NASH Model is a human liver microtissue specifically designed for the study of mechanisms of non-alcoholic steatohepatitis (NASH) induction and in vitro screening of anti-NASH drug efficacy. The model includes all the critical liver cells and inducers needed to recapitulate the inflamed fatty liver disease state and serves as a powerful model for NASH drug discovery and development.

Eva will discuss how our 3D NASH model recapitulates key physiological aspects of the NAFLD spectrum of diseases, including steatosis, inflammation, and fibrosis, and describe how it can be used with high-throughput screening approaches for assessing efficacy of anti-NASH drugs.

Conference Detail

  • Conference Dates: Jan 20-24, 2019
  • Presentation: Poster Session 3, Poster Number: 3015, Poster Session 3